[Electroencephalographic determination of vigilance following DL-propiramfumarate].
D000577:Amides / Q000494:pharmacology*; D000700:Analgesics / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001288:Attention / Q000187:drug effects*; D002110:Caffeine / Q000494:pharmacology; D002986:Clinical Trials as Topic; D003061:Codeine / Q000494:pharmacology; D004357:Drug Synergism; D004569:Electroencephalography; D004585:Electrooculography; D000431:Ethanol / Q000494:pharmacology*; D005133:Eye Movements / Q000187:drug effects; D005260:Female; D005650:Fumarates / Q000494:pharmacology; D006801:Humans; D008297:Male; D010615:Phenacetin / Q000494:pharmacology; D010634:Phenobarbital / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D010919:Placebos; D011398:Promethazine / Q000494:pharmacology*; D011422:Propionates / Q000494:pharmacology*; D011725:Pyridines / Q000494:pharmacology
D000577:Amides; D000700:Analgesics; D005650:Fumarates; D010880:Piperidines; D010919:Placebos; D011422:Propionates; D011725:Pyridines; D002110:Caffeine; D000431:Ethanol; D010615:Phenacetin; D011398:Promethazine; D001241:Aspirin; D003061:Codeine; D010634:Phenobarbital
Elektroenzephalographische Vigilanzbestimmungen nach DL-Propiramfumarat. Vergleiche mit Promethazin, Plazebo und Alkohol